Figures & data
Table 1 Patients’ Characteristics
Table 2 Changes in the Relative Eosinophil Count and Neutrophil-to-Eosinophil Ratio Before and Three Weeks After Pembrolizumab
Figure 1 The overall survival in patients treated with pembrolizumab according to the pretreatment relative eosinophil count and neutrophil-to-eosinophil ratio. *P values are reported.
![Figure 1 The overall survival in patients treated with pembrolizumab according to the pretreatment relative eosinophil count and neutrophil-to-eosinophil ratio. *P values are reported.](/cms/asset/ec636ba3-4761-4c4f-8e08-a7f398113663/dcmr_a_12189987_f0001_b.jpg)
Figure 2 The overall survival in patients treated with pembrolizumab according to the change of relative eosinophil count and neutrophil-to-eosinophil ratio at three weeks after pembrolizumab. *P values are reported.
![Figure 2 The overall survival in patients treated with pembrolizumab according to the change of relative eosinophil count and neutrophil-to-eosinophil ratio at three weeks after pembrolizumab. *P values are reported.](/cms/asset/bae7cd64-72f5-42cf-8eb8-aea3826d8630/dcmr_a_12189987_f0002_b.jpg)
Table 3 The Univariate and Multivariate Analyses of the Factors Associated with the Overalls Survival in Patients Receiving Pembrolizumab Treatment